PolyPeptide Gains Buyout Interest as Turnaround Progress Builds Momentum
Shares of Swiss drugmaker PolyPeptide (PLYGF) surged after reports of potential acquisition interest from major private equity firms like EQT, KKR, and Advent. The company's improved financial performance and operational recovery have increased its valuation to approximately CHF1.2 billion, marking its highest level in over three years. The turnaround aligns with growing demand in its niche market of peptide-based pharmaceutical ingredients.
Topics: Company Valuation M&A Stock Performance Turnaround Strategy